Top

Tumor Biology

Published in:

01-09-2016 | Original Article

Inhibition of protein methylesterase 1 decreased cancerous phenotypes in endometrial adenocarcinoma cell lines and xenograft tumor models

Published in: Tumor Biology | Issue 9/2016

Title: Inhibition of protein methylesterase 1 decreased cancerous phenotypes in endometrial adenocarcinoma cell lines and xenograft tumor models
Publication date: 01-09-2016
Published in: Tumor Biology / Issue 9/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5036-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 9/2016

Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo

Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells

The value of plasma netrin-1 in non-small cell lung cancer patients as diagnostic and prognostic biomarker

Multiple roles of CD90 in cancer

Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1

Shorter telomeres and high telomerase activity correlate with a highly aggressive phenotype in breast cancer cell lines

Keynote webinar | Spotlight on antibody–drug conjugates in cancer